Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.

MLA

Brekelmans, Marjolein P. A., et al. “Clinical Impact and Course of Major Bleeding with Edoxaban versus Vitamin K Antagonists.” Thrombosis and Haemostasis, vol. 116, no. 1, July 2016, pp. 155–61. EBSCOhost, https://doi.org/10.1160/TH15-11-0892.

APA

Brekelmans, M. P. A., Bleker, S. M., Bauersachs, R., Boda, Z., Büller, H. R., Choi, Y., Gallus, A., Grosso, M. A., Middeldorp, S., Oh, D., Raskob, G., Schwocho, L., & Cohen, A. T. (2016). Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis, 116(1), 155–161. https://doi.org/10.1160/TH15-11-0892

Chicago

Brekelmans, Marjolein P A, Suzanne M Bleker, Rupert Bauersachs, Zoltan Boda, Harry R Büller, Youngsook Choi, Alex Gallus, et al. 2016. “Clinical Impact and Course of Major Bleeding with Edoxaban versus Vitamin K Antagonists.” Thrombosis and Haemostasis 116 (1): 155–61. doi:10.1160/TH15-11-0892.